

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF FIRST DOSING OF FIRST PATIENT OF
ANTI-TSLP FULLY HUMAN MONOCLONAL ANTIBODY
(HBM9378) IN ASTHMA PHASE I TRIAL IN CHINA

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce the completion of the dosing of the first subject in phase I trial in China of HBM9378 (or SKB378, as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“**Kelun-Biotech**”), a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd (SZSE stock code: 002422) and the Company’s partner in the development of HBM9378), a fully human antibody targeting thymic stromal lymphopoietin (“**TSLP**”), for the treatment of moderate-to-severe asthma.

HBM9378 is a co-development project conducted by the Company and Kelun-Biotech, who together equally share the global rights in respect of HBM9378. Its long half-life optimization and outstanding biophysical properties support the favorable dosing advantage. According to the strategic collaboration and license agreement between the Company and Kelun-Biotech, the parties will jointly explore innovative therapies of monoclonal antibodies and antibody-drug conjugates.

Building on the Company’s innovative business model leveraging its productive R&D platform to lead the next generation of valuable and innovative therapies and its aim to address the unmet medical needs, the Company will follow its global innovation and development strategy and advance the global clinical development project of HBM9378 at full speed.

About HBM9378/SKB378

HBM9378 is a fully human monoclonal antibody against TSLP generated from two heavy chains and two light chains (H2L2) platform. It inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. TSLP plays important roles in DC cell maturation, T helper 2 (Th2) cell polarization and inflammation, particularly in both eosinophilic and non-eosinophilic inflammation asthma.

About Asthma

Asthma is a heterogeneous disease defined by the history of respiratory symptoms (e.g. wheeze, shortness of breath, chest tightness and cough) that vary over time and in intensity, together with variable expiratory airflow limitation. The disease is estimated to affect more than 300 million people worldwide and affect more than 45.7 million adults (≥ 20 years) in China. Approximately 5-10% of those afflicted with asthma have severe disease that is poorly controlled. Despite the use of medium to high dose inhaled corticosteroids (ICS) in combination with a long-acting $\beta 2$ -agonist (LABA), currently available biologic therapies and oral corticosteroids (OCS), many severe asthma remain uncontrolled. Current biologics are mainly targeting Type 2 severe asthma which manifests clinically with a combination of peripheral eosinophilia, sputum eosinophilia and/or elevated fractional exhaled nitric oxide (FENO).

Severe asthma patients experience frequent exacerbations, significant limitations on lung function and a reduced quality of life. The healthcare burden associated with care for these patients is also high. Therefore, there are still significant unmet needs to develop safer and broader therapies for severe asthma.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM9378. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 27 September 2022

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive directors.